TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in Pregnanediol Glucuronide (PdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Left Atrial enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MACE composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best overall objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of patient judged pruritus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uterine dimensions and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of nasal mucosa repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease burden in ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in sexual intentions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in risky sexual behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of teratoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median Number of Participant Transfusions Required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VAS scores postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative opioids analgesics requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sustained Pain Free (SPF) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Local Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of Strain-specific Hemagglutination Inhibition (HI) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary and Fecal Excretion of LY2801653 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: calculated renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Without a Device Related Adverse Events Within 1 Month of the Study Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Without a Type I, III, and/or IV Endoleak at 1 Month Follow-up Identified by Computed Tomography (CT)
Endpoint domain: Adverse events/effects
Primary endpoint: adipose macrophage content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adipose IL-6 and TNF gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: insulin regulation of lipolysis (IC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Frequency of Drinking Prior to Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Typical Number of Drinks Consumed Prior to Sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frequency of Condom Use During Sex Involving Alcohol
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Final cure rate or complete cicatrization of the ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Composite of all cause death, any stroke, any myocardial infarction (MI), and any (repeat) revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of patient reorientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Non-hemorrhagic stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of vascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Test Replicability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation marker (Ki-67)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral sensory neuropathy severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression-free Survival > 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Serum Haemagglutination-inhibition (HI) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-ESD bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: S100 B protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Pain Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in SC atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subcutaneous oxygen dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy and synchronization between patient and ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dorsolateral Prefrontal Cortex Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of confirmed HITS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: occurrence of venous thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of a major bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of clinically relevant non-major-bleeding, minor-bleeding or non-bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: Time to maximal 13C appearance in breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: septal to lateral wall delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early residual neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Total Unified Multiple System Atrophy Rating Scale (UMSARS Part I and II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Adhesions at the Retrosternal Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-operative Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Adhesion Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of 1-year grade 3 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative Opioid Use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ghrelin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma niacin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Value of DOB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of initial hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: recommended phase II doses (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in mood ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in short-term recognition memory ratings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in attention ratings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of life after renal transplantation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 6 hour post-operative Morphine Requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of succinate accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of cases with identified circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: workload or performance enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Astigmatic corneal decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with solicited local and systemic reactogenicity symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting spontaneous adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Immune response in terms of number of seroconverted subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune response in terms of number of seroprotected subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in objective daytime cough frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Framingham Point Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Diagnosed With Hirschsprung-associated Enterocolitis (HAEC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of Clinical Episodes of HAEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: stress symptoms change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: burnout risk change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life change perceived in visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in semen analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in reproductive hormone measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Score change of the AOFAS Hallux metatarsophalangeal interphalangeal scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects still using LoFric Origo
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time Taken to Complete Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of using the LINQ device for epilepsy diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using the LINQ device for monitoring epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using the LINQ device for management of epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ottawa Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hepatic VLDL-TG secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripheral VLDL-TG clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hepatic and adipose VLDL-TG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quantitative Helicobacter Pylori IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Outcome after invasive fungal infection
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With an Adjudicated On-trial Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of pancreatic insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peak enzyme Concentration IE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients requiring completion thyroidectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage change from Pre-Test to Post-Test referral
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Hospitalization Events
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: RAGE response measured in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of Life changes using EORTC QLQ-30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life changes using CES-D
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity and specificity of GAG recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: audiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of HPV testing to identify CIN2 or worse disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of routine colposcopy to identify CIN2 or worse disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arthralgia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR) 12 Weeks After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of conditioned pain modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC[0-tau])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+ and CD4+ peptide-reactive T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Recurrent kidney stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients with a >= 2-fold increase in tumor-infiltrating cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Midazolam Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of emerging virus specific B cell receptor variable regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in skin lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of patients maintaining HCT < 45%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with studies completed in < 7 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients assigned to novel treatment group
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical response rate (complete and partial responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of insulin independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Completion of post-transplant neurocognitive intervention program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma Certolizumab Pegol Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operational pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalization for acute heart failure, myocardial infarction, stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: time to maximum glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Significant Medical Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mitral Regurgitation (MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum neurotrophins with developmental delays
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in serum neurotrophins with respiratory outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Child aggressive behavior and prosocial skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall severity of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rest Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the Epi proColon test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in carotenoid concentration in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in retinyl esters concentration in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of sight-threatening adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time profile (AUCinf) of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) with TPS ≥50%
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) with TPS ≥20%
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) with TPS ≥1%
Endpoint domain: Mortality/survival
Primary endpoint: histological quantification of interstitial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oncological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Jugular venous pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lumbar Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography of Erector Spinae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Electromyography of Biceps Femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in aortic aneurysm morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Patients With PSA Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of positive bedside ultrasound scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total score on MADRS scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of PERSp in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Imaging diagnostic quality of hysterosalpingography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in average pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in NIH-stroke scale (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Arterial blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ Cell Count Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with an etiological diagnosis of endocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as measured by adverse event reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the lumbar puncture restraint board
Endpoint domain: Adverse events/effects
Primary endpoint: Participants Who Achieve 5 or More Percent Body Weight Reduction (Yes/no)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in primary biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding at 6 Weeks Post Delivery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lead time of tumor relapse detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients achieving PPE grade 0 or 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Receiving at Least a 1-grade Improvement in PGIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean WOMAC pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes